{"id":"W3081745704","doi":"10.1093/ndt/gfaa234","title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Janssen Pharmaceuticals; Defense Acquisition Program Administration; Sanofi Genzyme; Merck Sharp and Dohme; Satellite Healthcare; Alexion Pharmaceuticals; University of Glasgow; Steno Diabetes Center Copenhagen; Menarini Group; Novo Nordisk; Omeros Corporation; Astellas Pharma; Cytokinetics; Fresenius Medical Care North America; Daiichi-Sankyo; ReCor Medical; Alnylam Pharmaceuticals; Servier; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; World Health Organization; Ultragenyx Pharmaceutical; GlaxoSmithKline; Amgen; Angion; Pfizer; CSL Behring; AstraZeneca; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Kidney disease; Adverse effect; Internal medicine; Baseline (sea); Intensive care medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002401831,0.0001278931,0.0003499865,0.00009315179,0.00004426793,0.000005660911,0.00005257043,0.00005514205,0.00003962324],"category_scores_gemma":[0.0001136455,0.00009336831,0.0000968784,0.0001606888,0.00007888271,0.00008291232,0.000009896359,0.00007614311,0.000007335434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003799162,"about_ca_system_score_gemma":0.0000918829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001304972,"about_ca_topic_score_gemma":0.00006872576,"domain_scores_codex":[0.9989473,0.0001406114,0.0003973823,0.0002167839,0.0001427754,0.0001552118],"domain_scores_gemma":[0.9993967,0.0001547394,0.0001326652,0.0001406647,0.00003222468,0.0001430454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1816381,0.002056539,0.6295064,0.003032162,0.004261134,0.0003803171,0.004275197,0.0002768008,0.02485222,0.002520635,0.001142057,0.1460585],"study_design_scores_gemma":[0.08395851,0.002282874,0.8939109,0.0001154998,0.006780822,0.00000124022,0.00007763274,0.005689661,0.0005633531,0.0002216494,0.006174235,0.000223653],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910407,0.0001485463,0.001043378,0.006570384,0.00007733527,0.0009523918,0.00005555349,0.00003197795,0.0000797004],"genre_scores_gemma":[0.9955042,0.002005823,0.0001140594,0.001319134,0.00008745471,0.00009255219,0.0007491732,0.00001117463,0.0001164269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2644045,"threshold_uncertainty_score":0.3807449,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01526134839490754,"score_gpt":0.2661466598261347,"score_spread":0.2508853114312271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}